Work

Sacituzumab govitecan (IMMU-132) for patients with pretreated metastatic urothelial uancer (UC): interim results

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx371.012

Authors: S.T. Tagawa, B. Faltas, E. Lam, P. Saylor, A. Bardia, J. Hajdenberg, A.K. Morgans, E. Lim, K. Kalinsky, D.P. Petrylak, M. Guarino, M.D. Galsky, P. Maliakal, B. Mudenda, R. Sharkey, W. Wegener, D. Goldenberg

Institutions: Weill Cornell Medicine, University of Colorado Denver, Massachusetts General Hospital, UF Health Cancer Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center, Yale University, Smilow Cancer Hospital, Christiana Care Health System, Icahn School of Medicine at Mount Sinai, Immunomedics (United States)

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: AstraZeneca, University of Southern California, University of Pittsburgh, Case Western Reserve University, Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, USC Norris Comprehensive Cancer Center, Weill Cornell Medical College, Medical Center, University of Pittsburgh, National Cancer Institute

OpenAlex ID: W2762429515

FWCI: 3.786

Cites:

Cited by: 20

Related to: 10